Vendor Intelligence Report: Peptide Gurus

Published 12 Jun 2026. 24-page investigative report on who is behind Peptide Gurus: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Peptide Gurus is a product-specific case, not a simple yes/no vendor call. Across 46 Finnrick lab tests the overall pass rate is 20% (9 pass / 37 fail). Semaglutide is the lone stronger line in the blind record, while Retatrutide, BPC-157, and Ipamorelin are the clearest avoidance signals; ratings also shift under stricter methodology, so mid-range percentages can hide repeated failures.

The identity trail does not match the domestic storefront. Peptide Gurus presents Glendale, AZ and American-manufactured language, but archived site history, Chinese contact infrastructure, supplier listings using Peptide Gurus-branded product images, and unedited Chinese-template artifacts point toward the Shanghai Longyu / Lotusland supplier network. No matching Peptide Gurus-branded Arizona, UK, or OpenCorporates registration surfaced in the searched records.

Buyer risk is amplified by recourse and authentication gaps. Reported payment rails include peer-to-peer apps, PayPal Friends & Family, wire/Western Union, and crypto; a public non-delivery allegation exists but remains unverified. The report also found no independent Finnrick sterility/endotoxin data for this dossier, and no authoritative channel or anti-counterfeit system to resolve shipments under related labels such as NextGen Pharma.

Inside the full report:

  • Appendix A with per-product pass/fail rates, methodology-divergence charts, and rating trajectories for all 8 tested products
  • Wayback and certificate-timeline evidence showing the Lotusland-to-Peptide Gurus brand transition
  • ChemicalBook, Made-in-China, and Longyu Pharma artifacts tying the retail brand to Shanghai Longyu / Lotusland
  • Arizona, UK Companies House, and OpenCorporates registry checks for the Peptide Gurus Ltd / Glendale posture
  • NextGen Pharma sister-brand analysis and label-authentication guidance for buyers
  • Payment-channel review and community allegation handling, including what Finnrick did and did not verify

Risk assessment

  • Corporate-origin misrepresentation risk — high: Peptide Gurus presents as Peptide Gurus Ltd in Glendale, AZ / American-manufactured; records link the brand to Shanghai Longyu/Lotusland in China and no matching AZ/UK/OpenCorporates entity surfaced.
  • Product-quality risk for non-Semaglutide products — high: Non-Semaglutide lines are fail-heavy: BPC-157, Ipamorelin and Retatrutide are 0/7; CJC-1295 is 1/6; Tirzepatide is 2/7; Melanotan II and PT-141 are 0/3.
  • Payment and buyer-recourse risk — high: Reported channels include Venmo/Zelle/CashApp, PayPal Friends & Family, wire/Western Union and crypto; PeptideSource users reported Venmo no-notes instructions.
  • Brand-authentication and sister-brand confusion risk — medium: Lotusland and NextGen Pharma ties, including a reported NextGen shipment and now-for-sale nextgenpharma.to, create label/source confusion without an authoritative reseller/channel list.
  • Community non-delivery allegation risk — medium: A Reddit user alleged approximately $50,000 in non-delivery losses involving an owner called Johnny; allegations are unverified but material given payment-recourse limits.
  • Injectable sterility/endotoxin validation gap — medium: No independent Finnrick sterility/endotoxin data surfaced for Peptide Gurus; public claims of sterility/endotoxin failures remain uncorroborated.